However, in a human renal cell carcinoma dataset with anti‐PD‐1 treatment, we revealed that NFIL3 is highly expressed in the response group compared with the nonresponse group (Figure 6C). The gene discussed is NFIL3; the disease is hereditary clear cell renal cell carcinoma.